Clinical trial
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in…
NCT00468169 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00468169 |
|---|---|
| Title | Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer |
| Official title | A Randomized Phase II Trial of Concurrent Chemoradiation With Cetuximab (ERBITUX®), 5 Fluorouracil, Hydroxyurea, and Twice-daily Radiation (CetuxFHX) Versus Cetuximab (ERBITUX®), Cisplatin, and Accelerated Radiation With Concomitant Boost (CetuxPX) After Induction Chemotherapy in Patients With… |
| Acronym | EPIC |
| Lead sponsor | University of Chicago, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Cetuximab, 5-FU, Hydroxyurea, Twice-daily radiation, Cisplatin, Accelerated fraction radiotherapy with concomitant boost |
| Enrollment | 110 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | May 2, 2007 |
| Last update posted | Oct 9, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: